Posted by Michael Wonder on 21 Jul 2026
Oncolytics Biotech receives fast track designation for pelareorep in second-line and later anal cancer
20 July 2026 - Oncolytics Biotech today announced that the US FDA has granted fast track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal who have progressed on or were intolerant to one or more prior lines of systemic therapy.
The designation is supported by encouraging efficacy demonstrated in the Company’s GOBLET study evaluating pelareorep in combination with a checkpoint inhibitor in patients with advanced squamous cell carcinoma of the anal canal whose disease had progressed following prior therapy.
